News

COTA’s real-world data and Kite's drug development pipeline will complement single-arm clinical trials to accelerate cancer research benefiting patients.

MHE's Briana Contreras spoke with Dr. Ami Parekh, chief medical officer of Grand Rounds. Ami and Briana talked about the rise of the chief medical officer role, how businesses can benefit from it and what it means for the future of the C-suite. They also discussed how Ami's role as a CMO, and other C-Suite positions, evolved during the pandemic and why it is so essential for businesses to provide advice and clinical guidance to help best keep operations running safely.

The phase 2 TOPAZ trial demonstrated treatment is safe and improves motor function in patients with SMA.

Grand Rounds and Doctor On Demand merge to revolutionize how millions of Americans receive healthcare in a first of its kind patient-centric virtual care organization.

The pandemic has brought patient self-service to the fore.

Screening and some care have been canceled or deferred. Will more illness and deaths result?

Companies are working on a 2-drug regimen of Gilead's lenacapavir and Merck’s islatravir.

The State of Texas remains to recover from the winter storm blackout back in February. While the state still has much rebuilding and catching back up to do by covering damages and other economic losses, new operations among the state's and nation’s healthcare providers are coming out of it.

Multiple sclerosis (MS) is a chronic disease that involves demyelination of plaque throughout the white and gray matter of the central nervous system. The early stages of MS are usually marked by a relapsing-remitting course of neurological deficits, which progress toward continuous, permanent dysfunction and disability. Of those with a diagnosis of MS, 74% are women.

The efficiency and ease of tools that support virtualization will set the stage for the future of cancer care.

Patients with chronic conditions like asthma, diabetes, and cardiovascular disease often require emergency attention and hospitalization due to non-adherence, resulting in higher treatment costs.

Providers and payers need data to address social determinants of health effectively. But that data is often siloed, unstructured and difficult to use.

Devices take some of the pressure off a healthcare system coping with COVID-19.

After accelerated approval, both drugs fall short of overall survival endpoint. They will stay on the market for other indications.

The U.S. Preventative Services Task Force recently released an updated recommendation addressing lung cancer screening criteria at a sooner rate starting at 50-years-old rather than 55. The task force says this expansion will be especially helpful to those who face disparities to screening. Although, it won’t cover all disparities.

Population-level study of Medicare beneficiaries shows marked improvement in survival statistics but also an 8.6% jump in Medicare spending.

New drug may be a treatment option for people with the sixth most common type of cancer.

Companies could be hit with a double peak of claims for COVID-19 patients and care that people put off because of the pandemic.

The short answer is yes. Automation and data insights can help get COVID-19 vaccines into people’s arms faster. A fragmented healthcare system in the U.S. makes scaling up any system difficult.

Briana Contreras, associate editor of MHE, spoke with Sheila Talton, founder and CEO of Gray Matter Analytics, in this week's episode of Tuning In to the C-Suite podcast. In the discussion, Sheila addressed the topic of how healthcare organizations are missing out by not actively expanding their efforts to seek out and fast track talented individuals across many minority populations, especially in the c-suite.

Patient centricity and physician leadership were among the keys of success of a program that increased the proportion of same-day total hip and knee replacement from 7.2% to 62% in a span of three years.

Kristin Ficery, who leads Accenture’s North America Health, discusses recent Accenture research that discovered since the onset of COVID-19, 60% of patients want to use technology more for their healthcare. And nine out of 10 patients said quality of care was “as good or better” than before COVID-19.

Federal assistance programs and telehealth have helped, but they haven’t made up for the shortfall from lack of services.

The still-experimental oral antiviral drug has been compared to Tamiflu but would be for COVID-19 not the flu.

In a short address, Broussard also discussed Humana's success in the Medicare Advantage program and expanding access to healthcare.

Thomas P. Leist, MD, PhD, a neurologist and professor of Multiple Sclerosis at Jefferson University Hospitals, is the latest guest featured on MHE Talks: Improving Patient Access podcast. In this episode, Thomas spoke with Peter Wehrwein, senior editor of Managed Healthcare Executive, about accessing care amongst patients with MS through therapies, health insurance barriers, options of step therapy and more.

The decision by Roche comes shortly after AstraZeneca withdrew the bladder cancer indication for durvalumab (Imfinzi).

Healthcare has successfully pivoted and collaborated. But COVID-19 also has spotlighted flaws in how hospitals are financed and the weakness of the public health infrastructure.

Market research firm sees growth in sales for injectable therapies developed with an eye toward improving adherence. Sales in pre-exposure prophylaxis are also projected to increase.